The Pharmacokinetics of Dexmedetomidine in Volunteers with Severe Renal Impairment
Authors:
- Andre M. De WolfAWAndre M. De Wolf
- Robert J. FragenRFRobert J. Fragen
- Michael J. AvramMAMichael J. Avram
- Paul C. FitzgeraldPFPaul C. Fitzgerald
- Farhad Rahimi-DaneshFRFarhad Rahimi-Danesh
- 1 November 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 93 (5) , 1205-1209
Abstract
Dexmedetomidine, an α2-adrenergic agonist with sedative and analgesic properties, is mainly cleared by hepatic metabolism. Because the pharmacokinetics of dexmedetomidine have not been determined in humans with impaired renal function, we studied them in volunteers with severe renal disease and in control volunteers. Six volunteers with severe renal disease and six matched volunteers with normal renal function received dexmedetomidine, 0.6 μg/kg, over 10 min. Venous blood samples for the measurement of plasma dexmedetomidine concentrations were drawn before, during, and up to 12 h after the infusion. Two-compartmental pharmacokinetic models were fit to the drug concentration versus time data. We also determined its hemodynamic, respiratory, and sedative effects. There was no difference between Renal Disease and Control groups in either volume of distribution at steady state (1.81 ± 0.55 and 1.54 ± 0.08 L/kg, respectively; mean ± sd) or elimination clearance (12.5 ± 4.6 and 8.9 ± 0.7 mL · min−1 · kg−1, respectively). However, elimination half-life was shortened in the Renal Disease group (113.4 ± 11.3 vs 136.5 ± 13.0 min;P < 0.05). A mild reduction in blood pressure occurred in most volunteers. Although most volunteers were sedated by dexmedetomidine, renal disease volunteers were sedated for a longer period of time.Keywords
This publication has 12 references indexed in Scilit:
- Developing and Testing Integrated Multicompartment Models to Describe a Single-Input Multiple-Output Study Using the SAAM II Software System1998
- Compartmental Models: Theory and Practice Using the SAAM II Software System1998
- Postoperative Pharmacokinetics and Sympatholytic Effects of DexmedetomidineAnesthesia & Analgesia, 1997
- Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidineEuropean Journal of Clinical Pharmacology, 1994
- The Pharmacokinetics and Hemodynamic Effects of Intravenous and Intramuscular Dexmedetomidine Hydrochloride in Adult Human VolunteersAnesthesiology, 1993
- Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidineClinical Pharmacology & Therapeutics, 1992
- Tissue‐Specificity of Hydroxylation and N‐Methylation of ArylalkylimidazolesBasic & Clinical Pharmacology & Toxicology, 1991
- Dexmedetomidine, an α2-Adrenoceptor Agonist, Reduces Anesthetic Requirements for Patients Undergoing Minor Gynecologic SurgeryAnesthesiology, 1990
- Biotransformation of medetomidine in the ratXenobiotica, 1990
- Picogram level determination of medetomidine in dog serum by capillary gas chromatography with negative ion chemical ionization mass spectrometryJournal of Chromatography B: Biomedical Sciences and Applications, 1989